Noven Pharmaceuticals Appoints Chief Financial Officer

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced the appointment of James B. Messiry, age 56, as Vice President & Chief Financial Officer. In his role, Mr. Messiry will be responsible for the supervision and direction of all of Noven's financial and business development activities.

Prior to joining Noven, Mr. Messiry served the Bacardi-Martini Group for over 13 years in a variety of senior executive offices, including as President of BSC Corporation (Miami, Florida); Vice President of Bacardi, Ltd. (Miami, Florida); Managing Director of Bacardi-Martini B.V. (Amsterdam, Holland); and Finance Director of Bacardi International (Hamilton, Bermuda).

Prior to his recent service at the Bacardi organization, Mr. Messiry served as a senior executive for a number of consumer products companies. At Dole Foods, he served as Vice President - Finance for Dole Dominicana (Santo Domingo, Dominican Republic), an agroindustrial unit of Dole. At Beatrice Foods, Mr. Messiry served as Director of Finance for Beatrice Latin America (Miami, Florida), a division comprised of 25 companies in 12 countries. In the Pfizer organization (New York and Sao Paulo, Brazil), Mr. Messiry served in management and in financial, strategic and operations planning roles.

Mr. Messiry holds an MBA degree from Columbia University Graduate School of Business, and a BA degree from George Washington University.

Leonard Maniscalco, who served Noven as its Interim Chief Financial Officer, will continue to serve Noven as its Executive Director of Finance.

"Jim brings a valuable set of finance, business development and strategic planning skills developed during 25 years of service at some of the best known and most successful organizations in the world," said Robert Strauss, Noven's President and Chief Executive Officer. "His diverse, multinational experience will help us accomplish our goal of broadly commercializing the products of both Noven and Vivelle Ventures LLC."

Vivelle Ventures LLC is a women's health products company jointly owned by Noven and Novartis Pharmaceuticals. Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leader in the development of advanced drug delivery technologies.

Noven's existing products include advanced estrogen transdermal delivery systems (Vivelle®, licensed to Vivelle Ventures LLC, and Menorest, licensed to Rhône-Poulenc Rorer); combination estrogen/progestogen transdermal delivery systems (CombiPatch™ and Estalis®, licensed to Rhône-Poulenc Rorer); and the first transmucosal patch delivery system approved by the FDA (DentiPatch®, developed, marketed and sold by Noven). With a range of additional products in development, Noven is committed to becoming the world's premier developer, manufacturer and marketer of transdermal and transmucosal drug delivery systems.

Forward-looking statements contained herein are qualified by and subject to the risks and uncertainties specified by Noven in its most recent filings with the Securities and Exchange Commission.